Ascend Wellness posted Q2 net Revenue of $126.1 million, a 7.9% sequential rise over the prior quarter, while retail revenue climbed 11.5% to $92.7 million. The growth showcases the company’s expanding store network and higher‑margin sales, supporting stronger Cash Flow and positioning it for an upcoming uplisting.

Key Highlights

  • Retail revenue rose 11.5% sequentially to $92.7 million as the store count grew to 55 locations
  • Those figures highlight the impact of a rapidly expanding store network and a shift toward higher‑margin branded sales.
  • Net revenue climbed to $126.1 million from $116.9 million in Q1, marking a 7.9% sequential increase.

Those figures highlight the impact of a rapidly expanding store network and a shift toward higher‑margin branded sales.

Q2 Revenue Surge

Net revenue climbed to $126.1 million from $116.9 million in Q1, marking a 7.9% sequential increase. Retail sales drove the bulk of the gain, rising to $92.7 million versus $83.1 million a month earlier, while wholesale revenue slipped slightly to $33.4 million from $33.8 million. Adjusted gross profit Margin edged higher to 46.2% from 46.1%, reflecting a modest mix shift toward higher‑margin products.

The revenue acceleration underscores the effectiveness of Ascend’s retail‑centric strategy in a contracting market, but the modest wholesale decline signals pricing pressure that could reappear if inventory turns weaken.

Retail Footprint Expansion

A strategic Partnership in Ohio is poised to add both owned and partner‑run stores after pending license approvals. Combined Market Share across the seven‑state footprint rose roughly 5% sequentially, and total retail transactions grew about 7%, confirming that the added doors are translating into measurable consumer activity.

Profitability and Cash Generation

Net loss narrowed dramatically to $9.8 million from $29.5 million a quarter earlier.

Upcoming Uplisting Vote

Ascend filed a definitive proxy statement to approve a Reverse Stock Split of its Class A common shares, setting the special shareholders’ meeting for August 28. The split is intended to satisfy listing standards of a major U.S. exchange, a strategic move that could broaden the investor base and improve liquidity. Concurrently, the company applied to the DEA for expedited registration of its state‑licensed medical operations under the new Schedule III pathway.

A work stoppage at the Barry, Illinois Facility that began June 25 was resolved by August 3, limiting the quarter’s impact but prompting close monitoring of third‑quarter results. Management forecasts a 2‑4% revenue rise in Q3 and expects adjusted EBITDA margin to remain at the Q2 level, making the upcoming Shareholder vote and the subsequent uplisting a key catalyst for valuation re‑rating.

Peers Moving on This News